Owatari Satsuki, Arai Akihiko, Tsuruta Tomoko, Haraguchi Koichi, Otsuka Maki, Hanada Shuichi
J Clin Exp Hematop. 2015;55(1):29-31. doi: 10.3960/jslrt.55.29.
A case of secondary acute myeloid leukemia (AML) was identified following adult T-cell leukemia/lymphoma (ATL), for which combination chemotherapy had been administered, including epipodophyllotoxin, anthracycline, and alkylating agents. AML with maturation was diagnosed by the cytological findings, cell surface markers, and chromosomal abnormalities. We previously reported two cases of AML accompanied by ATL. In this case of AML after chemotherapy for ATL, we considered that the AML was probably associated with previous chemotherapy for ATL. Although the ATL remained in remission, the therapy-related AML with complex chromosomal abnormalities proved resistant to chemotherapy, and the patient died from complications associated with AML.
1例成人T细胞白血病/淋巴瘤（ATL）患者在接受包括表鬼臼毒素、蒽环类药物和烷化剂在内的联合化疗后确诊为继发性急性髓系白血病（AML）。通过细胞学检查结果、细胞表面标志物和染色体异常诊断为成熟型AML。我们之前曾报道过2例伴有ATL的AML病例。在这例ATL化疗后发生AML的病例中，我们认为AML可能与之前ATL的化疗有关。尽管ATL仍处于缓解期，但具有复杂染色体异常的治疗相关AML对化疗耐药，患者死于与AML相关的并发症。
